

Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis

Stephanie Humblet-Baron,^{1,2} Blythe Sather,^{3,4} Stephanie Anover,¹ Shirley Becker-Herman,¹ Debora J. Kasprovicz,⁴ Socheath Khim,¹ Thuc Nguyen,¹ Kelly Hudkins-Loya,⁵ Charles E. Alpers,⁵ Steve F. Ziegler,^{3,4} Hans Ochs,¹ Troy Torgerson,¹ Daniel J. Campbell,^{3,4} and David J. Rawlings^{1,3}

¹Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA. ²Center for Cellular and Molecular Therapy, University of Liege, Liege, Belgium. ³Department of Immunology, University of Washington School of Medicine, Seattle, Washington, USA.

⁴Benaroya Research Institute, Seattle, Washington, USA. ⁵Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA.

Wiskott-Aldrich syndrome protein (WASp) is essential for optimal T cell activation. Patients with WAS exhibit both immunodeficiency and a marked susceptibility to systemic autoimmunity. We investigated whether alterations in Treg function might explain these paradoxical observations. While WASp-deficient (WASp^{-/-}) mice exhibited normal thymic Treg generation, the competitive fitness of peripheral Tregs was severely compromised. The total percentage of forkhead box P3-positive (Foxp3⁺) Tregs among CD4⁺ T cells was reduced, and WASp^{-/-} Tregs were rapidly outcompeted by WASp⁺ Tregs in vivo. These findings correlated with reduced expression of markers associated with self-antigen-driven peripheral Treg activation and homing to inflamed tissue. Consistent with these findings, WASp^{-/-} Tregs showed a reduced ability to control aberrant T cell activation and autoimmune pathology in *Foxp3*^{-/-} *Scurfy* (*sf*) mice. Finally, WASp⁺ Tregs exhibited a marked selective advantage in vivo in a WAS patient with a spontaneous revertant mutation, indicating that altered Treg fitness likely explains the autoimmune features in human WAS.

Introduction

Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency disorder characterized by opportunistic, viral, and bacterial infections due to abnormal lymphocyte function. Affected individuals also have thrombocytopenia with small platelets, eczema, and increased risk of autoimmune disorders and malignancies (1). Worldwide, more than 200 unique mutations have been described within the gene encoding the WAS protein (WASp) (reviewed in ref. 2). Mutations leading to loss of WASp expression correlate with a more severe disease phenotype (3). WASp mRNA is expressed in all hematopoietic lineages, and WASp participates in multiple signal transduction pathways in a range of cell types. WASp deficiency, however, is most prominently associated with defects in T lymphocyte function. WASp^{-/-} T cells fail to polymerize and reorganize actin in response to anti-CD3 stimulation, and formation of the T cell immunological synapse is defective. Thus, WASp deficiency appears to directly interfere with assembly of the TCR “signalosome,” resulting in incomplete cellular activation and, consequently, decreased cell proliferation and cell survival.

Patients with WAS exhibit a very high prevalence of autoimmune disease. In one study more than 70% of patients (40/55 evaluated) had 1 or more autoimmune episodes, including autoimmune cytopenias, arthritis, vasculitis, inflammatory bowel disease, or renal disease (1, 4). Autoimmune manifestations in WAS typically present very early in life and are largely unresponsive to medical therapy. In addition, WAS patients with autoimmune disease manifest a poorer clinical prognosis (3). Further, even patients with otherwise mild disease (thrombocytopenia only)

due to mutations permitting low-level expression of intact protein or of a partially functional protein can develop life-threatening autoimmune sequelae (3). The high prevalence of autoimmunity in WAS might result from escape of self-reactive T cells from negative selection due to defective TCR-mediated signals and reduced apoptosis at this checkpoint. Alternatively, chronic inflammatory stimuli, defects in IL-2 production, or alterations in APC or macrophage function have each been suggested as explanations of these disease associations (5, 6). In this study, we tested to determine whether these paradoxical observations, immunodeficiency in association with life-threatening autoimmunity, might be explained on the basis of defects in Treg function and altered dominant tolerance.

Naturally occurring CD4⁺ Tregs mediate dominant control of self-reactive T cells and thereby play a crucial role in maintenance of immunologic self tolerance (reviewed in refs. 7, 8). Tregs are generated in the thymus, and the development of this population is critically dependent upon expression of the forkhead box transcription factor, forkhead box P3 (Foxp3), which serves as the best marker to identify both thymic and peripheral Tregs. Recent evidence indicates that the TCR repertoire of Tregs is likely to be as broad as that of other naive T cells, enabling Tregs to recognize both self and nonself antigens. While much has been learned with regard to the generation and functional properties of Tregs, relatively less is known with regard to their in vivo activation, including, in particular, the specific signals that control Treg expansion and tissue localization. Such signals are likely to be crucial in mediation of the distinct downstream regulatory activities of activated Tregs.

We show that WASp^{-/-} mice, like WAS patients, develop early onset, high-titer autoantibodies. We also show that restoration of WASp expression in humans promotes the expansion of Tregs. Consistent with both of these observations, WASp^{-/-} Tregs fail to compete effectively in vivo and are unable to maintain immunologic

Nonstandard abbreviations used: CFSE, carboxy-fluorescein diacetate, succinimide ester; DN, double negative; dsDNA, double-stranded DNA; Foxp3, forkhead box P3; *sf*, *Scurfy*; SP, single positive; ssDNA, single-stranded DNA; WAS, Wiskott-Aldrich syndrome; WASp, WAS protein.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 117:407–418 (2007). doi:10.1172/JCI29539.




Figure 1

WT Tregs are expanded in a WAS patient following reversion of a pathogenic mutation. Peripheral blood mononuclear cells were analyzed by flow cytometry using antibodies to CD4, CD45RA, CD27, CD62L, WASp, and FOXP3. (A) Characterization of the CD4⁺FOXP3⁺ (Tregs) and CD4⁺FOXP3⁻ (effector T cell [T_{EFF}]) cell populations within the total lymphocyte gate. (B) WASp expression within the CD4⁺FOXP3⁺ Treg population demonstrating that approximately 25% of the patient's Tregs are WASp⁺. (C) Identification of the naive CD4⁺CD27⁺CD45RA⁺ T cells within the CD4⁺FOXP3⁺ T_{EFF} cell population. Naive cells account for approximately 7% of the T_{EFF} population in this patient. (D) Within the naive T cell compartment, only a small proportion of the cells (approximately 2%) are WASp⁺. (E) In comparison with the T_{EFF} population, very few (<1%) CD27⁺CD45RA⁺ naive cells are present within the CD4⁺FOXP3⁺ Treg population. (F and G) Within the CD4⁺FOXP3⁺ Treg population, WASp⁺ cells account for equal percentages of the CD62L⁺ (F) and CD62L⁻ (G) Treg subsets.

tolerance in Treg-deficient mice. Finally, we show that the percentage of Tregs expressing adhesion molecules and chemoattractant receptors required for nonlymphoid tissue entry is uniformly reduced in WASp^{-/-} Tregs, suggesting a defect in peripheral Treg activation. Taken together, our findings indicate that Treg homeostasis is critically reliant upon signals integrated by WASp and suggest a crucial role for WASp in antigen-driven Treg expansion and control of basal T and B cell activation in normal hosts.

Results


Expansion of differentiated WASp⁺ Tregs in a WAS patient with a revertant mutation. We recently identified a WASp^{-/-} patient who exhibited an improved clinical picture in association with new evidence for WAS expression within his T, B, and NK cells. This teenaged patient had suffered from lifelong, recurrent episodes of autoimmune hemolytic anemia beginning at 15 months of age. WASp reexpression correlated with stabilization of his rbc count and reduction in his steroid therapy over the preceding 6–9 months. Previous diagnostic studies had identified a single-nucleotide deletion in WAS leading to a frameshift and premature stop codon as well as absence of WASp expression. These genetic studies were repeated using peripheral blood lymphocytes and a newly derived T cell line and identified a new single-nucleotide insertion at the same genomic site. This change was predicted to restore the normal amino acid sequence and normal WASp expression (T. Torgerson, H. Ochs, and D.J. Rawlings, unpublished observations).

This revertant mutation provided a unique opportunity to evaluate the consequences of restored WASp function in newly

generated lymphoid populations. Consistent with the reversion having an impact on a limited progenitor pool, only approximately 2% of naive CD4 T cells (e.g., CD4⁺CD45RA⁺CD27⁺CD62L⁺ cells) expressed WASp (Figure 1, C and D). In contrast, we observed a striking increase in relative percentage of WASp⁺ Tregs (25%–35% CD4⁺FOXP3⁺ cells expressed WASp; Figure 1B). Similar results were obtained in 3 independent analyses over time. To define the relative expression of WASp within maturing Tregs, we also used markers to identify CD45RA⁺CD27⁺, CD45RA⁻CD27⁺, and CD45RA⁻CD27⁻ Tregs (Figure 1E). Based upon these staining criteria, very few CD45RA⁺CD27⁺ naive cells were present within the CD4⁺FOXP3⁺ Treg population. We also evaluated the expression of CD62L within the CD4⁺FOXP3⁺ Treg population. WASp⁺ cells accounted for 24% and 27% of the CD45RA⁻CD62L⁺ and CD45RA⁻CD62L⁻ subsets, respectively (Figure 1, F and G). In contrast, CD45RA⁺CD62L⁺ Tregs accounted for less than 1% of the total Treg population, and the very small number of such cells precluded analysis of the relative percentage of WASp⁺ cells within this naive population (due to the lymphopenia present in this patient). These results suggest that WASp⁺ human Tregs manifested a strong *in vivo* selective advantage and raise the question of whether WASp plays a critical role in Treg homeostasis.

WASp^{-/-} mice develop high-titer anti-DNA autoantibodies and autoimmune disease. WASp-deficient (WASp^{-/-}) mice (9, 10) provide a useful model for human WAS. These animals exhibit clear defects in T cell function, including abnormal actin cytoskeletal organization, reduced CD3 and CD3/CD28 proliferative responses, and markedly reduced IL-2 production. Despite the striking clinical data in human WAS, however, there is only limited evidence that WASp^{-/-} mice develop autoimmunity. The 129SvEv/WASp^{-/-} strain (9) develops spontaneous, radiation-induced colitis that resembles autoimmune inflammatory bowel disease. We have also observed spontaneous subclinical colitis and frequent rectal prolapse in WASp^{-/-} mice backcrossed into the C57BL/6 background (data not shown). Thus, this inflammatory disease association, while less severe, does not appear to be strain specific as previously suggested (11).

Notably, no previous studies have evaluated whether WASp^{-/-} mice exhibit defects in B cell tolerance or develop humoral autoimmune features analogous to those commonly observed in patients with WAS. To address this question, we initially screened a cohort of aged WASp^{-/-} and control animals for evi-

**Figure 2**

WASp^{-/-} mice develop high-titer autoantibodies, and WT Tregs expand and rescue transplanted WASp^{-/-} mice from autoimmune colitis. Presence of IgG dsDNA autoantibodies in the serum of (A) 129SvEv (129sv) or (B) C57BL/6 (Black-6) WASp^{-/-} mice versus age- and sex-matched WT controls or 25- to 38-week-old BWF1 mice (positive control). Antibody titers were assessed by ELISA ($n = 3-6$ animals for each strain/sex). 2°Ab control, background values obtained using secondary antibody alone. Error bars represent SD. (C) WASp expression within T and B cells (CD3 and B220, respectively) but not myeloid cells allows for a competitive advantage over time in lethally irradiated WASp^{-/-} recipients (129SvEv strain) transplanted with a 1:3 mixture of WT to WASp^{-/-} BM cells. Peripheral blood from 5 mice was serially analyzed by flow cytometry at the indicated times after transplant to determine the percentage of WASp⁺ T, B, or myeloid cells. (D) The selective advantage of WASp-expressing cells within the T cell compartment is most marked in the peripheral Treg subset. WASp^{-/-} mice (129SvEv strain) were transplanted as in C, and WASp expression among the indicated T cell populations was evaluated 12 months after transplant. WASp⁺ myeloid cells remain at the same percentage as when originally transplanted (approximately 25%), indicating no selective advantage. Recipients of WT:WASp^{-/-} mixed BM transplants did not develop fatal, radiation-induced colitis, which occurred in all recipients of WASp^{-/-} BM (data not shown). DP, CD4⁺CD8⁺ thymocytes; PLN Tregs, peripheral lymph node Tregs.

dence of antinuclear antibodies and observed a marked increase in both anti-single-stranded DNA (anti-ssDNA) and anti-double-stranded DNA (anti-dsDNA) antibodies (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI29539DS1). To determine the timing and frequency of autoantibody production, we followed cohorts of WASp^{-/-} and control mice of both sexes and of both genetic backgrounds. Compared with age-matched WT controls, WASp^{-/-} mice demonstrated a consistent increase in both anti-dsDNA and anti-histone antibodies by 3 months of age (Figure 2, A and B, and Supplemental Figure 1B). Significantly, titers of anti-DNA antibodies in 6-month-old WASp^{-/-} mice were equivalent to those in 6- to 9-month-old female NZB/W F₁ mice, a well-characterized murine model of systemic lupus erythematosus (12). Together, our data demonstrate that WASp^{-/-} mice develop high-titer antinuclear antibodies with high frequency early in life, indicating that WASp deficiency promotes alterations in B cell tolerance.

Chimeric BM transplantation promotes WT Treg expansion and rescues WASp^{-/-} from irradiation-induced colitis. Irradiation promotes the rapid onset of inflammatory colitis in WASp^{-/-} mice (129SvEv strain). This complication is prevented by transplantation with WT but not WASp^{-/-} bone marrow. For example, 11 of 12 WASp^{-/-} animals developed severe colitis requiring sacrifice following radiation doses of 550–950 cGy and transplantation with WASp^{-/-} BM whereas no animals transplanted with WT BM developed this complication (data not shown). Because of these observations, we decided to determine whether induction of colitis in this model was due to a cell-intrinsic defect in tolerance induction of the WASp^{-/-} cells. To this end, bone marrow (1×10^7 containing a 1:3 chimeric mixture of WT versus WASp^{-/-} cells) was transplanted into lethally irradiated 129SvEv WASp^{-/-} mice to establish stable mixed chimeras. In lieu of congenic markers, we utilized WASp intracellular staining as a highly sensitive assay to identify WASp⁺ and WASp^{-/-} hematopoietic cells. Recipient animals exhibited





Figure 3

WASp^{-/-} Tregs fail to control autoimmunity in *sf* mice. Male Ly5.1 *sf* neonates (>3 days of age) were injected i.p. with 1×10^6 to 2×10^6 CD4⁺CD25⁺-enriched WT or WASp^{-/-} Tregs (both Ly5.2), sacrificed at 30–45 days after cell transfer, and evaluated for levels of T cell activation and tissue inflammation. **(A)** WT Tregs but not WASp^{-/-} Tregs prevent development of activated *sf* lymphocytes. Lymphocytes isolated from the spleen and lung parenchyma of recipient mice were stained for CD4, Ly5.1, CD44, and CD45RB. The relative percentage of activated CD44^{hi}CD45RB^{low} T cells in each tissue is shown. All plots are gated on CD4⁺Ly5.1⁺ cells to identify recipient-derived cells, and donor cell source is indicated above each panel. Controls included age-matched, unmanipulated *sf* and WT animals. **(B)** Graph represents the percentage of CD44^{hi}CD45RB^{low}-activated, recipient-derived cells (CD4⁺Ly5.1⁺) among all recipient animals. Each point represents data from 1 *sf* recipient of either WASp^{-/-} ($n = 5$) or WT ($n = 2$) Tregs. **(C)** WT Tregs but not WASp^{-/-} Tregs rescue *sf* mutant mice from development of autoimmune infiltration of major organs. Formalin-fixed liver and lung tissue from *sf* mice that received WT versus WASp^{-/-} Tregs were paraffin embedded, sectioned, and stained with H&E to visualize tissue structure and inflammatory cell infiltration. Liver and lung sections from unmanipulated *sf* and WT mice are shown for comparison. Original magnification, $\times 10$.

a progressive accumulation of WASp⁺ B and T cells (reaching approximately 40% at 10 weeks and 65%–75% by 50 weeks after transplantation; Figure 2C). Similar findings were previously reported (11) and indicate that WASp expression provides a selective advantage to both T and B cells under these conditions. Interestingly, while detailed phenotypic analysis of T cell subsets indicated only limited selection for WASp⁺ cells within the thymus and naive T cell pool, we observed a preferential expansion of WASp⁺ Tregs. The relative numbers of WASp⁺ Tregs reached nearly 100% at the time of sacrifice (12 months after transplantation; Figure 2D). In contrast, we observed no advantage for WASp⁺ myeloid cells (Gr-1⁺ and Mac⁺ cells), which were maintained at levels equivalent to the initial chimeric mixture (25%–30%; Figure 2C and data not shown). Notably, none of the transplanted mice developed overt signs of colitis, and histological analysis at the time of sacrifice was indistinguishable from that for age-matched WT controls (data not shown). Thus, WT cells ameliorated the colitis mediated by WASp^{-/-} cells, and this correlated with a preferential expansion of WASp⁺ Tregs within WASp^{-/-} hosts.

Transfer of WASp^{-/-} Tregs fails to control autoimmunity in neonatal Scurfy recipient mice. Because WASp⁺ effector T cells and B cells were also partially selected in vivo in our chimeric bone marrow transplant experiments, these studies were insufficient to determine whether defects in Treg function were principally responsible for the autoimmune features observed in WASp^{-/-} mice. Male *Scurfy* (*sf*) mice lack all Tregs due to a spontaneous mutation in Foxp3 and suffer from severe multiorgan autoimmunity, resulting in death by 3–4 weeks of age. Adoptive transfer of even very small numbers of WT Tregs ($\sim 10^5$) can prevent the *sf* autoimmune syndrome (7). Therefore, we used this model to directly test for cell-intrinsic in vivo defects in WASp^{-/-} Treg function independent of any contribution of functional defects in WASp^{-/-} effector T cells. Male *sf* pups received purified WT Tregs (as a control for prevention of autoimmunity) or WASp^{-/-} Tregs via adoptive transfer. In each case, donor Tregs (Ly5.2) were transferred into nonirradiated C57BL/6 (Ly5.1/Ly5.2 heterozygous) neonatal *sf* recipients. As previously described, unmanipulated *sf* animals exhibited severe lymphadenopathy, splenomegaly, and

**Figure 4**

WASp is not required for generation of Tregs within the thymus. (A) WASp is not required for the production of peripheral Tregs. Peripheral LN cells from WT or WASp^{-/-} animals were stained simultaneously for CD4, CD25, and Foxp3 and evaluated by flow cytometry. Note that Foxp3⁺ Tregs are present in WASp^{-/-} mice albeit at a slightly decreased percentage. (B) WASp^{-/-} and WT mice have a similar percentage of Tregs (CD4⁺ CD25⁺ Foxp3⁺) within the CD4⁺ SP thymic population. Both 6- and 16-week-old WT and WASp^{-/-} C57BL/6 mice ($n = 5$ for each age and strain) were evaluated. (C) The selective advantage of WASp⁺ T cells is not manifest in the thymus. The percentage of WASp⁺ cells was evaluated within various thymic cell subsets in 6- to 8-week-old WASp^{+/+} heterozygous female carriers (C57BL/6 strain) ($n = 5$). Error bars show SD. Relative WASp expression was not significantly different among any subset evaluated. DN, CD4⁻CD8⁻ thymocytes. Representative data from 1 of at least 3 experiments are shown.

phenotypic evidence for T cell activation and autoimmunity in all tissues examined. CD4⁺ T cells isolated from the spleen and lung parenchyma expressed elevated levels of the activation marker CD44 and reduced expression of the naive T cell marker CD45RB (Figure 3A). Histological analysis of liver and lung, 2 particularly susceptible tissues in *sf* mice, revealed extensive lymphocytic infiltration and inflammation surrounding blood vessels in the liver and large and small airways in the lung (Figure 3C). In contrast, animals receiving adoptively transferred WT Tregs exhibited minimal T cell activation (Figure 3, A and B) and little or no histological evidence of lymphocytic inflammation in all tissues analyzed (lung and liver shown, Figure 3C). These findings were similar to those in unmanipulated WT control mice (Figure 3, A and C). Strikingly, recipients of WASp^{-/-} Tregs were unable to control aberrant activation of effector T cells (Figure 3, A and B) and developed marked splenomegaly and pulmonary and liver inflammatory changes that were similar to those in untreated *sf* mice (Figure 3C). Inflammatory cell infiltrates were also observed in other tissues, including skin and kidney (data not shown). Importantly, all Ly5.2⁺ cells were uniformly Foxp3⁺, indicating that the transferred cell populations were composed entirely of either WASp^{-/-} or WASp⁺ Tregs, respectively (data not shown). Taken together, these data demonstrate that WASp^{-/-} Tregs fail to effectively mediate dominant tolerance in vivo.

WASp^{-/-} mice generate normal numbers of Foxp3⁺ Tregs within the thymus. Based upon the in vivo functional deficit exhibited by WASp^{-/-} Tregs, we next sought to determine whether WASp deficiency had an impact specifically on either Treg generation, in vitro Treg function, or in vivo homeostasis. To address the role of WASp in Treg production, we identified Tregs in WT versus WASp^{-/-} animals using 2 independent staining protocols (Figure 4A). Tregs were readily identified in WASp^{-/-} mice as based on either the CD3⁺CD4^{int}CD25^{hi}CD69⁻ or CD4Foxp3⁺ cell phenotype. There was no difference in either the relative percentage or absolute numbers of CD4⁺Foxp3⁺ cells in the thymi of WT versus WASp^{-/-} mice in either the C57BL/6 or 129SvEv strains (Figure 4B and data not shown).

To more precisely assess the role for WASp thymic Treg production, we evaluated WASp expression in thymic T cell subsets isolated from WASp^{+/+} heterozygous female mice. This approach allowed us to identify any developmental stage(s) at which WASp⁺ cells might manifest a selective advantage based upon nonrandom inactivation of the X-linked WAS gene. One previous study has suggested that BM progenitor cells derived from WASp^{+/+} heterozygous mice exhibit early nonrandom X inactivation (13). However, intracellular WASp staining of both BM B cell progenitors and myeloid cells from heterozygous animals was consistent with a random X-inactivation pattern, with 50% of cells in both lineages expressing WASp (Supplemental Figure 2A





Figure 5 *WASp*^{-/-} Tregs exhibit in vitro suppressive activity. CD4⁺CD25⁻ effector T cells (T_{EFF}) and CD4⁺CD25⁺ cells (Tregs) were isolated from WT or *WASp*^{-/-} mice (C57BL/6 strain). WT or *WASp*^{-/-} T_{EFF} were labeled with CFSE and plated as targets with WT or *WASp*^{-/-} Tregs at the Treg/T_{EFF} (target) ratios noted in the presence of irradiated APCs. Cultures were stimulated with 3 μg/ml anti-CD3 and 1 μg/ml anti-CD28 for 110 hours. Relative CFSE dilution was measured in cultures containing WT (A) or *WASp*^{-/-} (B) targets. Unstimulated and control-stimulated (CD3/CD28 without Tregs) cells are shown in the left panels.

and data not shown). Our data suggest that previous findings may reflect a selective advantage of *WASp*⁺ cells for growth in colony-forming assays. The relatively limited role of *WASp* in murine versus human HSC function might reflect redundant activity of neural *WASp* or related proteins.

Using this staining method, we observed little or no difference in the relative percentage of *WASp*⁺ cells within any thymic developmental stage, from double negative (DN) to single positive (SP). The median number of *WASp*⁺ cells increased slightly between the DN and SP stages, reaching a level of slightly greater than 50% in CD4⁺ and CD8⁺ SP thymocytes (Figure 4C). While a previous report (10) suggested that *WASp* deficiency impairs the double-negative 3 (DN3) to DN4 transition, we also observed no significant change in the relative percentage of *WASp*-expressing cells at this stage (data not shown). Most notably, the median level for *WASp* expression in thymic Foxp3⁺ Tregs was essentially identical to that of the total CD4⁺ SP thymocytes in young (6–8.5 weeks) and aged (6 months) heterozygous mice (Figure 4C and data not shown). Thus, *WASp* is not essential for generation of Tregs in the thymus.

WASp^{-/-} Tregs exhibit in vitro suppressive activity. We used in vitro T cell suppression assays to directly determine whether *WASp* was required for Treg-suppressive activity. Spleen and LN CD4⁺CD25⁻ effector T cells were labeled with carboxy-fluorescein diacetate, succinimidyl ester (CFSE) or left unlabeled, then cultured with increasing numbers of WT or *WASp*^{-/-} CD4⁺CD25⁺ Tregs. All cultures also contained irradiated CD4-depleted WT APCs and were stimulated with agonistic anti-CD3 and anti-CD28 monoclonal antibodies. When tested with WT effector T cells, *WASp*^{-/-} Tregs exhibited moderately reduced suppressor activity at all target ratios, based upon either CFSE dilution or thymidine incorporation as independent measures for effector proliferation (Figure 5A and data not shown). To better mimic the in vivo situation in *WASp*^{-/-} mice, we also evaluated the relative suppressor activity of WT versus *WASp*^{-/-} Tregs with respect to *WASp*^{-/-} effectors. Under these conditions (Figure 5B), WT and *WASp*^{-/-} Tregs functioned equivalently at all target ratios. Additionally, we compared the suppressive activity of WT versus *WASp*^{-/-} Tregs across a range of anti-CD3 cross-linking to determine whether *WASp*

**Figure 6**

WASp^{-/-} Tregs demonstrate a competitive disadvantage *in vivo*. (A) Heterozygous female carriers (6 months) demonstrate marked skewing within the Treg population. Naive T cells from peripheral blood (CD3⁺CD62L⁺CD44⁻) and Tregs from peripheral LNs (CD4⁺CD25⁺CD69⁻) were analyzed for relative WASp expression by flow cytometry. Mean \pm SD is shown with the results of the paired 2-tailed Student's *t* test. Identical results were obtained using CD4⁺Foxp3⁺ staining to identify Tregs. PEC, peritoneal cavity exudate; MLN, mesenteric lymph node. (B) WASp confers selective advantage during peripheral maturation/expansion of Tregs. The Treg population in different tissues from 6- to 8-week-old WASp^{+/-} heterozygous mice (C57BL/6 strain) was evaluated for WASp expression by flow cytometry gated on the CD4⁺Foxp3⁺ population. Paired 2-tailed Student's *t* test results indicate significant differences between peripheral lymphoid and thymic Tregs. (C) WASp^{-/-} mice have lower Treg numbers than WT mice. CD4⁺Foxp3⁺ Tregs were evaluated in different tissues in WT versus WASp^{-/-} C57BL/6 mice (ages 6 weeks to 6 months) and displayed as relative percentage of Tregs within the live cell gate. Pooled data were compared using the Mann-Whitney *U* test.

deficiency impaired Treg function in the context of suboptimal CD3 engagement. Again, WT and WASp^{-/-} Tregs functioned similarly at each CD3 concentration evaluated (data not shown; Treg/effector T cell ratio of 1:1). Together, these findings indicate that, in contrast with the marked *in vivo* functional deficit observed following adoptive transfer, Treg activation and function *in vitro* are largely intact in the absence of WASp. Further, because WASp^{-/-} Tregs efficiently suppressed WASp^{-/-} effectors, alterations in Treg function appeared insufficient to explain the autoimmune phenotype of WASp-deficient mice or humans.

WASp^{-/-} Tregs fail to compete effectively *in vivo*. While WASp was not required for the generation or *in vitro* activity of Tregs, we reasoned that defects in Treg homeostasis might account for the failure of WASp^{-/-} Tregs to control self reactivity *in vivo*. To address this issue, we first analyzed the relative numbers of WASp⁺ versus WASp^{-/-} Tregs within peripheral lymphatic tissues of WASp^{+/-} heterozygous female mice. An example of this analysis is provided in Supplemental Figure 2B. While only approximately 55% of naive T cells were WASp⁺, more than 90% of peripheral Tregs were WASp⁺ (Figure 6A; *P* < 0.009). This skewing was obvious by 6 weeks of age, maintained in older animals, and evident in all lymphoid tissues as well as in cells isolated from nonlymphoid sites, including the peritoneal cavity (peritoneal cavity exudate cells) and lung airways (bronchoalveolar lavage fluid cells) (Figure 6B and data not shown).

We also determined whether the apparent selective advantage of WT Tregs observed in heterozygous WASp^{+/-} mice was reflected in alterations in the relative numbers of Tregs in WASp^{-/-} animals (Figure 6C). While the frequency of thymic Tregs was not different in 6-, 16-, and 24-week-old WT versus WASp^{-/-} animals, the percentage of CD4⁺Foxp3⁺ Tregs was consistently reduced in all peripheral lymphoid compartments in WASp^{-/-} animals. This reduction was present in mice at all ages evaluated in both C57BL/6 and 129SvEv WASp^{-/-} strains (Figure 6C and data not

shown). Because WASp^{-/-} mice also exhibit a modest reduction in total CD4⁺ T cell numbers, this change resulted in an approximate 30% reduction in the number of total CD4⁺Foxp3⁺ splenic Tregs compared with WT animals. Notably, we observed no significant differences in relative percentage(s) of CD3⁺, CD4⁺, or CD8⁺ cells within the peripheral lymphatic compartment compared with controls. This finding was consistent with a preferential loss of Tregs within the peripheral T cell pool in WASp^{-/-} animals.

Purified WASp^{-/-} Tregs expand poorly in neonatal recipient mice. Homeostatic maintenance of Tregs in nonlymphopenic hosts is dependent upon both TCR signals and exogenous IL-2 provided via CD4⁺CD25^{low}Foxp3⁻ T cells (14, 15). Exogenous IL-2 levels are predicted to be decreased in WASp^{-/-} mice due to the deficit in TCR-mediated IL-2 production (9, 10), and this might limit the expansion/function of WASp^{-/-} Tregs. To test this possibility, WT (Ly5.1) and WASp^{-/-} (Ly5.2) Tregs were isolated and cotransferred (2×10^6 to 6×10^6 total Tregs/recipient) into non-irradiated, neonatal C57BL/6 (Ly5.1/Ly5.2) *sf* recipients. Upon transfer, purified WT Tregs undergo extensive homeostatic expansion (7). Thus, by cotransferring WT and WASp^{-/-} Tregs into neonatal *sf* mice, we could directly compare their ability for homeostatic expansion and survival in the context of normal IL-2 production and in the absence of endogenous Tregs. Adoptively transferred Tregs were identified using antibodies to the Ly5.1 (CD45.1) versus Ly5.2 (CD45.2) allotype markers beginning at 14 days after transfer (Figure 7A). WASp^{-/-} Tregs were rapidly outcompeted by the cotransferred WT Tregs, indicated by their progressive decline from spleen and LNs within 20–30 days after transfer (Figure 7, A and B). Thus, IL-2 provided *in trans* by normal effector T cells does not appear to be sufficient to rescue homeostatic proliferation of WASp^{-/-} Tregs.

Impaired peripheral differentiation of WASp^{-/-} Tregs. The majority of Tregs undergo cell division following transfer into nonlymphopenic hosts (14, 15), and proliferating Tregs in naive animals acquire a distinct activated cell surface phenotype, including downmodulation of CD62L and increased expression of CD44, CD69, and other activation markers (15). To determine whether WASp may play an important role in Treg activation, we asked whether WASp⁺ versus WASp^{-/-} Tregs derived from WASp^{-/-} carriers differed with regard to expression of these markers. WASp⁺




Figure 7 Purified WASp^{-/-} Tregs fail to expand and compete effectively in vivo. Male *sf* neonates (>4–5 days of age) heterozygous for Ly5.1 and Ly5.2 were injected i.p. with a 50:50 mixture of WT (Ly5.1) and WASp^{-/-} (Ly5.2) CD4⁺CD25⁺ Tregs. Peripheral blood lymphocyte samples were analyzed at biweekly intervals starting at 14 days of age to measure the relative levels of donor Tregs. **(A)** Representative temporal analysis of the relative numbers of WT versus WASp^{-/-} Tregs. FACS analysis of input (left panel) CD4⁺CD25⁺-enriched WT/WASp^{-/-} Treg mixture stained for Ly5.1 and Ly5.2 (middle and right panels). Analysis of the relative level for each donor population within the CD4⁺Foxp3⁺ gate at time points indicated. Peripheral blood lymphocyte samples were costained for CD4, Foxp3, Ly5.1, and Ly5.2. **(B)** Graphic depiction of the relative percentage of WASp^{-/-} Tregs remaining at each time point in 3 animals, based upon phenotypic analysis as described in **A**.

Tregs consistently expressed higher levels of both CD44 and CD69 and reduced levels of CD62L (data not shown). Essentially identical results were obtained using either CD4^{int}CD25^{hi} or CD4⁺Foxp3⁺ gates (as in Figure 4A) to define Treg subsets. These findings suggest that Treg activation preferentially promoted the expansion of WASp^{-/-} cells.

Notably, Tregs are thought to be targeted to nonlymphoid sites only after self-antigen recognition within lymphoid tissues. Thus, Tregs have been subdivided based on homing receptor expression into populations with differential tropism for lymphoid versus nonlymphoid tissues (reviewed in ref. 16). Tregs expressing the αE chain (CD103) of the integrin CD103 β 7 also preferentially express homing receptors that target cells to nonlymphoid tissues, including P selectin and E selectin ligands, $\beta 1$ integrin, CCR4, and CCR6 (17, 18). While CD103⁻ and CD103⁺ Tregs exhibit similar *in vitro* suppressor activities, they exhibit the distinct capacity to suppress *in vivo* immune responses. Naive CD4⁺ T cell activation in lymphoid tissues is effectively suppressed by CD103⁻ Tregs, whereas CD103⁺ Tregs home to inflammatory sites and preferentially suppress disease activity in inflammatory models (18, 19) or modulate the effector T cell response to local infection (20).

To determine the relative requirement for WASp in generation of tissue-tropic Treg subsets, we characterized cell surface expression profile of WASp⁺ versus WASp^{-/-} Tregs with regard to a series of candidate adhesion and homing receptors. Essentially identical data were obtained in analysis of Tregs isolated from spleen or from peripheral or mesenteric LNs (Figure 8 and data not shown). CCR7 is expressed by the vast majority of Tregs in lymphoid tissues, and accordingly, we observed no appreciable difference in the relative expression of this receptor on WASp⁺ versus WASp^{-/-} Tregs (Figure 8D). In contrast, both the relative percentage (Figure 8, C–E) and relative mean fluorescence intensity of CD103 expression (data not shown) were significantly reduced in WASp^{-/-} Tregs. Accordingly, the relative expression of P selectin and E selectin ligands, CCR4, and

CCR6 were also significantly reduced in WASp^{-/-} Tregs (Figure 8E). Although the number of cells available for analysis was relatively limited, we also observed an increase in CD103 expression in WASp⁺ Tregs isolated from bronchoalveolar lavage fluid and peritoneal cavity exudate (data not shown). Together, this phenotypic analysis supports the idea that WASp-dependent signals are required for optimal activation and functional differentiation of Tregs in the periphery.

Discussion

The data presented here strongly support a model in which signals mediated by WASp are essential for Treg homeostasis, peripheral activation, and *in vivo* function. While WASp exerts little or no role in thymic Treg production, WASp is required for peripheral Treg expansion and survival. WASp deficiency leads to a decreased percentage of Tregs among the peripheral CD4⁺ T cells and has a marked impact on the activated Treg pool, as shown by the decrease in Tregs that express activation markers and homing receptors associated with activation. Consistent with these observations, WASp^{-/-} Tregs exhibited decreased competitive fitness in 3 independent *in vivo* murine models, including heterozygous female carriers, recipients of chimeric bone marrow transplants, and Treg-deficient mice that received WASp^{-/-} Tregs via adoptive transfer. Further, expansion of WASp⁺ Tregs correlated with rescue of WASp^{-/-} recipients from radiation-induced inflammatory colitis, and conversely, WASp^{-/-} Tregs failed to mediate dominant tolerance after transfer into neonatal *sf* mice. Finally, consistent with each of these observations in mice and with the marked propensity for WAS patients to develop autoimmune sequelae, we observed a strong selective advantage for WASp⁺ human Tregs *in vivo* in a patient with a revertant mutation leading to reexpression of WAS in developing Tregs. In this case, the presence of this population correlated with decreased autoimmune disease activity and an improved clinical condition.




Figure 8

WASp^{-/-} Tregs demonstrate decreased homing receptor expression relative to WT Tregs. Female WASp^{+/-} heterozygous mice (C57BL/6 strain) were analyzed for expression of CCR4, CCR6, CCR7, P selectin and E selectin ligands, and CD103 in WASp⁺ versus WASp⁻ Tregs in different tissues (spleen, peripheral LNs, mesenteric LNs, peritoneal fluid). (A) Total lymphocytes were stained with CD4, Fcγ3, and WASp to identify Tregs (CD4⁺Fcγ3⁺, upper gate) or CD4⁺T_{EFF} (CD4⁺Fcγ3⁻, lower gate) cells. (B) Histogram of relative WASp expression in Tregs. (C) Histogram of WASp expression in the CD4⁺T_{EFF} compartment. (D) Example of the relative percentage of splenic WASp⁻ versus WASp⁺ Tregs that coexpress CD103. (E) Mean ± SD for relative percentage of splenic Tregs coexpressing specific adhesion/homing receptors and WASp (with P values based upon paired 2-tailed Student's *t* test). Similar data were obtained from other tissues. P sel. L, P selectin ligand; E sel. L, E selectin ligand.

than that in CD4⁺CD25⁻ T cells, and more that 80% of splenic Tregs undergo multiple cell divisions within 30 days of transfer into nonlymphopenic hosts (14, 15). Third, *in vivo* proliferating Tregs in unimmunized, healthy animals acquire a distinct activated cell surface phenotype that includes downmodulation of CD62L and upregulation of activation markers (CD44, CD69, GITR, CD134/OX40, CD122/IL-2Rβ, and others) (15) and non-lymphoid tissue homing receptors, including CD103 (18). Thus, the cycling CD44^{high} Tregs and CD103⁺ Treg populations largely overlap. Together, these observations suggest that Treg homeostasis is mediated by encounters with cognate self antigen presented within the draining LNs or spleen and that this promotes expression of activation markers and receptors essential for homing and tissue entry. This activated Treg population mediates dominant tolerance via at least 3 alternative means: inhibition of the priming of colocalized naive T cells in the secondary lymphoid tissues, entry into germinal centers and modulation of B cell activation, and suppression of activated effector T cells within nonlymphatic tissue sites. In contrast with this scenario, homeostatic cycling of naive CD4⁺CD25⁻ T cells proceeds in the absence of costimulatory molecules and does not lead to a stable alteration in activation markers or tissue tropism.

Our combined findings support the conclusion that WASp is essential for homeostatic Treg activation and suggest, but do not prove, that WASp is required for optimal self-antigen-driven proliferation *in vivo*. Interestingly, WASp^{-/-} Tregs exhibited normal suppressive activity against WASp^{-/-} effector T cells and only modestly reduced suppressive activity against WT effector T cells. Because thymic, naive, and activated Tregs behave similarly *in vitro* (15, 18), it is perhaps not surprising that this assay failed to identify defects secondary to alterations in the relative number of activated Tregs in WASp^{-/-} animals. In contrast with our *in vitro* findings, WASp function is clearly required for peripheral Treg survival and/or expansion. WASp functions to facilitate efficient T cell:APC synapse formation and sustained TCR signaling. Thus, our data suggest that WASp is required for efficient responses to cognate self antigen presented in a physiologic context *in vivo*. Further, while alterations in APC function might also limit Treg activation in WASp^{-/-} mice, our adoptive transfer data *in vivo* recipients demonstrate that cell-intrinsic defects are sufficient to abrogate WASp^{-/-} Tregs function *in vivo*.

Expression of CD103, P selectin and E selectin ligands, α4β7, CCR4, and CCR6 were all reduced in WASp^{-/-} Tregs. In addition, migration of WASp^{-/-} T cells is impaired due to their defects in

Thymic Treg development is dependent upon Fcγ3 expression, cytokine signaling via the common γ chain, and TCR-mediated positive selection (reviewed in refs. 7, 8). Interestingly, WASp appears to play a very limited role in this process. The number of thymic Tregs and their surface phenotypes were identical in WT and WASp^{-/-} mice, and Fcγ3 was also expressed at normal levels in WASp⁻ Tregs. Also, analysis of X inactivation in WASp^{+/-} mice revealed no evidence for altered fitness in thymic Tregs. We also failed to identify any differences in the TCR repertoire of WASp^{-/-} versus WT thymic Tregs in heterozygous animals using a panel of TCR Vβ antibodies (data not shown). While this analysis does not assess differences in TCR affinity, these combined observations suggest that TCR-mediated Treg selection is largely WASp independent. Further, while T cell-mediated IL-2 production is deficient in WASp^{-/-} mice, this deficit played no role in thymic Treg production, a finding consistent with recent work (21).

Tregs comprise a stable proportion of the steady-state CD4⁺ T cell population. Maintenance of the Treg pool is dependent upon signals provided via the TCR, IL-2, and costimulatory molecules, including CD28/B7-1/B7-2 (refs. 7, 14, 22, and reviewed in ref. 23). Mounting evidence, including the data presented here, argue that Treg homeostasis differs in crucial ways from homeostatic cycling of naive CD4⁺CD25⁻ T cells. First, compared with CD25⁻ T cells, Tregs appear to be significantly longer lived (15). Second, the basal proliferative response in Tregs is 2- to 5-fold greater



cytoskeletal rearrangement (24, 25). Together, these defects are predicted to limit the capacity of WASp^{-/-} Tregs to enter and function within inflamed tissue. Consistent with this, nearly all tissue-resident Tregs in heterozygous mice were WASp⁺ (data not shown). Defective Treg activation and migration may play an important role in the spontaneous and radiation-induced inflammatory colitis present in WASp^{-/-} mice. Also, recent work indicates that activated Tregs can enter B cell follicles in a chemokine-dependent fashion and modulate B cell activation (26–28). Thus, the striking increase in anti-DNA antibody levels in WASp^{-/-} animals may derive from a failure to regulate effector T cell activation and inefficient Treg homing to germinal centers and modulation of B cell activation. As BCR signaling is intact in WASp^{-/-} B cells (9, 10), loss of dominant tolerance directed toward activated B cells may have an enhanced phenotype in this context. Further studies are required to test this possibility and to determine whether restoration of WT Tregs alone is sufficient to abrogate autoimmunity in WASp^{-/-} animals.

Although Tregs cannot produce IL-2, their activation is tightly linked to IL-2 produced by activated CD4⁺CD25⁻ effector T cells, tying Treg responses to the inflammatory signals they modulate. While dispensable for Treg production and *in vitro* Treg activity, IL-2 provided in *trans* orchestrates a nonredundant growth and survival program in peripheral Tregs (21). Although WASp^{-/-} effector T cells exhibit defects in IL-2 production, restoring IL-2-producing capacity with normal effector T cells appears to be insufficient to rescue the peripheral expansion of WASp^{-/-} Tregs. This interpretation is consistent with the inability of WASp^{-/-} Tregs to compete effectively with WT cells in either heterozygous mice or Treg-deficient *sf* hosts. Defects in IL-2 production may, however, accentuate the competitive disadvantage of WASp^{-/-} Tregs in WASp^{-/-} mice and in human patients. As naive and activated Foxp3⁺ T cells rely on survival signals distinct from IL-2, this difference may further contribute to the overall reduction in peripheral Treg versus effector T cell pool size observed in WASp^{-/-} mice.

While WASp^{-/-} mice exhibit a marked defect in Treg activation and function, the autoimmune features of WASp^{-/-} mice and WAS patients are less severe than those present in either Foxp3 mutant mice or humans. Previous studies of WASp function may provide insight into these differences. First, concurrent defects in effector T cell activation may offset deficient Treg function by limiting basal self reactivity, expansion, or survival of the effector T cell pool. Second, the initial events driving effector T cell activation may also be blunted due to intrinsic alterations in APC function. Third, altered T helper or follicular dendritic cell function might limit the capacity of activated B cells to generate high affinity autoantibodies.

Human WAS carriers exhibit nonrandom X inactivation in hematopoietic lineages, including Tregs, due to a competitive advantage for WASp⁺ hematopoietic stem cells (2). This effect normally precludes any analysis of the relative competitive advantage for WASp function within human Tregs. However, identification of a WAS patient with a revertant mutation presumably affecting a lymphoid stem cell allowed us to directly demonstrate relative selective advantage for WASp-expressing Tregs in humans. At present, our findings are insufficient to directly link this improvement in competitive fitness with the clinical improvement in this individual patient. However, in light of our data in WASp^{-/-} animals, these observations strongly sug-

gest that alterations in Treg function may explain the high frequency of autoimmunity in WAS patients. Notably, 2 previous groups have identified WAS pedigrees with revertant mutations in lymphoid progenitors (29–31). Evaluation of WASp expression within Tregs in these other pedigrees and correlation of these data with autoimmune manifestations and analyses of the TCR repertoire of expanded Tregs in the patient described here and by others should provide important additional insight into the events mediating homeostatic Treg activation.

Methods

Mouse strains. The 129SvEv WASp^{-/-} and *sf*/C57BL/6 mice were obtained from The Jackson Laboratory. All studies were performed using the 129SvEv WASp^{-/-} strain (9) and a C57BL/6 WASp^{-/-} strain generated by backcrossing with C57BL/6 mice for 6–10 generations as well as WT controls. Mice were maintained in specific pathogen-free facilities of Seattle Children's Hospital or the Benaroya Research Institute and handled according to NIH and institutional guidelines. All experiments were approved by either the Animal Care and Use Committee of Children's Hospital and Regional Medical Center or the Benaroya Research Institute.

Cells and reagents. Single-cell suspensions were prepared from lymphoid tissues (thymus, spleen, and peripheral and mesenteric LNs). Peyer patches were excised from the intestine, disrupted into single-cell suspension, and filtered through 100- μ m nylon mesh for lymphocytes. Peritoneal and bronchoalveolar fluids were collected after lavage with cold sterile PBS. Erythrocytes were depleted by lysis with NH₄Cl₂ solution. Murine cells were cultured in RPMI with 10% FCS plus supplement (glutamine, 2-mercaptoethanol, penicillin and streptomycin, and 10 mM HEPES). Peripheral blood was obtained from WAS patients, carriers, and controls following informed consent obtained according to the Institutional Review Board guidelines of Children's Hospital of Seattle. Human peripheral blood mononuclear cells were isolated using Ficoll-Hypaque (Amersham Pharmacia) gradient centrifugation as previously described. Platelets were separated by low-speed centrifugation.

Flow cytometry. For cell-surface staining, 10⁶ cells per sample were incubated with various antibodies in staining buffer (PBS and 3% FCS) for 15 minutes on ice. Anti-murine antibodies included CD25 (PC61.5), CD8 (53–6.7), CD62L (MEL-14), CD3 (145-2C11), Gr-1 (RB6-8C5), CD103 (2E7), and Foxp3 (FJK-165) from eBioscience; and CD4 (RM4-5), CD44 (IM7), CD69 (H1.2F3), and CD11b (M1/70) from BD Biosciences – Pharmingen; and FOXP3 (259D) from BioLegend. Anti-human antibodies included FOXP3 (PCH101), CD27 (O323), and CD62L (Dreg56) from eBioscience; CD4 (RPA-T4), CD27 (M-T271), and CD45RA (HI100 and L48) from BD Biosciences – Pharmingen; and CD4 (13B8.2) from Beckman Coulter. Chemokine-IgG3 fusion proteins were used for flow cytometry of CCR4, CCR6, and CCR7 expression as previously described (32). To assess binding of CD4⁺ T cells to P selectin and E selectin, cells were sequentially incubated in either a P selectin or E selectin human IgM fusion protein (provided by J. Lowe, Case Western Reserve University, Cleveland, Ohio, USA) produced in COS-7 cells as previously described (33); this was followed by biotinylated goat anti-human IgM (Jackson ImmunoResearch Laboratories Inc.) and streptavidin-PE (eBioscience). Murine and human Foxp3 antibody-staining reagents were used according to eBioscience or BioLegend protocols, respectively. Purified polyclonal rabbit anti-WASp antibody was generated as previously described (34), and intracellular staining was performed according to instructions for the BD Biosciences – Pharmingen Fixation/Permeabilization Solution Kit, using FITC-conjugated anti-rabbit IgG secondary antibodies (Southern Biotechnology Associates) or Cy5- or PE-conjugated anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch



Laboratories Inc.). Data were acquired on a FACSCalibur or an LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo for Windows version 7.1 or FlowJo for Mac version 8.2 (Tree Star Inc.).

In vitro suppression assays. For CFSE assays, CD4⁺CD25⁻ cells (effector T cells) and CD4⁺CD25⁺ cells (Tregs) cells were isolated from spleen and LNs of WT or WASp^{-/-} mice via CD4⁺ isolation kit (Dyna); this was followed by separation of CD25⁺ and CD25⁻ fractions by CD25-PE plus anti-PE microbeads and fractionation via magnetic column (Miltenyi Biotech). CD4⁺ spleen cells from WT mice were irradiated at 50 Gy and used as APCs in all cultures. Effector T cells were incubated for 9 minutes at 37°C in 0.8 μM CFSE in PBS, washed with 100% FBS, resuspended in complete DMEM, and cultured as described in the Figure 5 legend. For thymidine assays, purified CD4⁺ cells were stained with CD4 and CD25 and FACS sorted (FACSaria cell sorter; BD Biosciences). WT CD4⁺CD25⁻ (5 × 10⁴) target cells and increasing numbers of WT versus WASp^{-/-} CD4⁺CD25⁺ Tregs (1.25 × 10⁴ to 5 × 10⁴) or CD4⁺CD25⁻ cells were added to achieve the correct Treg/target cell ratio in cultures also containing irradiated APCs. Cultures were stimulated with anti-CD3 for 72 hours. ³H-thymidine (1 μCi) was added per well during the last 8 hours of culture, and thymidine incorporation was measured in triplicate wells using a FilterMate Cell Harvester and TopCount Scintillation Counter (PerkinElmer).

ELISA assays. For detection of anti-dsDNA and anti-ssDNA antibodies, 96-well Immuno-Plates (Nunc) were coated with 0.01% poly-L-lysine solution in PBS (Sigma-Aldrich) and then with 100 μg/ml salmon sperm dsDNA, denatured salmon sperm ssDNA (Invitrogen), or histone from calf thymus (Sigma-Aldrich). After blocking with 0.5% BSA/PBS, serially diluted serum samples in 0.05% Tween 20/0.5% BSA/PBS were added to the plates in triplicate. Plates were washed with 0.05% Tween 20/PBS using a plate washer (SkanWasher 400; Molecular Devices), and goat anti-mouse IgG HRP (Southern Biotechnology Associates) diluted at 1:2,000 into 0.05% Tween 20/0.5% BSA/1% goat serum/PBS was added to each well. Peroxidase reactions were developed using BD Biosciences OptEIA TMB substrate and stopped with 2N H₂SO₄. OD405 was read using Victor 3 multilabel microplate counter (PerkinElmer). The OD readings from 3 wells were averaged for each serum sample.

Murine BM transplants and adoptive transfer purified Tregs. For mixed BM chimera analysis, WT and WASp^{-/-} BM was isolated, rbc were lysed, and 10⁷ total BM cells (containing 1:3 ratio WT and KO cells) were transplanted via intravenous injection into lethally irradiated (10.5 Gy) WASp^{-/-} recipient animals. Peripheral blood was periodically analyzed for WASp expression in different hematopoietic lineages. For neonatal transfers, CD4⁺CD25⁺ Tregs (>85% purity in all experiments) were isolated from the spleen and LNs of

8- to 12-week-old WT and WASp^{-/-} mice (C57BL/6 strain), as described for the CFSE assay. A minimum of 10⁶ Tregs (WT, WASp^{-/-}, or a 50:50 mix of WT and WASp^{-/-} cells) was transferred in 20 μl PBS via i.p. injection into male neonatal *sf* mice more than 3 days old. Mice were monitored for *sf* phenotype, bled to measure donor chimerism (via staining for Ly5.1/Ly5.2, CD4, and Foxp3) starting at 14 days, and sacrificed between 30 and 50 days after transfer for full histological and phenotypic analysis.

Tissue histology. Tissues were immersion fixed in 10% neutral buffered formalin, processed into paraffin, and stained with H&E, PAS, or periodic acid silver methenamine by standard protocols. Immunofluorescence was done on acetone-fixed frozen sections, as previously described (35).

Statistics. A paired 2-tailed Student's *t* test was used to compare the percentage of WASp⁺ and WASp^{-/-} cells within the same animal (e.g., heterozygote females), and the Mann-Whitney *U* test was utilized to compare the number of Tregs between WT and WASp^{-/-} mice.

Acknowledgments

We thank our WAS patients and families for participation; John Lowe and Fanny Ebling for providing reagents; Yulia Ovechkina, Ellen Renner, and Qili Zhu for technical assistance; and Angel Hui for editing assistance. S. Humblet-Baron was supported by a grant from Fonds National de la Recherche Scientifique (FNRS), Belgium (Televie), and by the Leon Frederiq Fund; B. Sather by a National Cancer Institute institutional training grant (T32-CA009537); and D.J. Campbell by a career development award from the Crohn's and Colitis Foundation of America. This work was also supported in part by NIH grants R01 CA81140, R01 HD37091, R01 HL075453, R01 DK072295, R01 DK66802, and P30 DK47754; pilot funding from the US Immunodeficiency Network (USIDNET); and the DeJoriaWiskott-Aldrich Research Fund.

Received for publication June 28, 2006, and accepted in revised form November 14, 2006.

Address correspondence to: David J. Rawlings, Department of Pediatrics, Children's Hospital & Regional Medical Center, 307 Westlake Avenue North, Suite 300, Seattle, Washington 98109, USA. Phone: (206) 987-7450; Fax: (206) 987-7310; E-mail: drawing@u.washington.edu.

Stephanie Humblet-Baron and Blythe Sather contributed equally to this work.

- Sullivan, K.E., Mullen, C.A., Blaese, R.M., and Winkelstein, J.A. 1994. A multiinstitutional survey of the Wiskott-Aldrich syndrome. *J. Pediatr.* **125**:876–885.
- Thrasher, A.J. 2002. WASp in immune-system organization and function. *Nat. Rev. Immunol.* **2**:635–646.
- Imai, K., et al. 2004. Clinical course of patients with WASP gene mutations. *Blood.* **103**:456–464.
- Dupuis-Girod, S., et al. 2003. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. *Pediatrics.* **111**:e622–e627.
- Burns, S., Cory, G.O., Vainchenker, W., and Thrasher, A.J. 2004. Mechanisms of WASp-mediated hematologic and immunologic disease. *Blood.* **104**:3454–3462.
- Schurman, S.H., and Candotti, F. 2003. Autoimmunity in Wiskott-Aldrich syndrome. *Curr. Opin. Rheumatol.* **15**:446–453.
- Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. *Nat. Immunol.* **4**:330–336.
- Sakaguchi, S., and Sakaguchi, N. 2005. Regulatory T cells in immunologic self-tolerance and autoimmune disease. *Int. Rev. Immunol.* **24**:211–226.
- Snapper, S.B., et al. 1998. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. *Immunity.* **9**:81–91.
- Zhang, J., et al. 1999. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. *J. Exp. Med.* **190**:1329–1342.
- Strom, T.S., Li, X., Cunningham, J.M., and Nienhuis, A.W. 2002. Correction of the murine Wiskott-Aldrich syndrome phenotype by hematopoietic stem cell transplantation. *Blood.* **99**:4626–4628.
- Borchers, A., Ansari, A.A., Hsu, T., Kono, D.H., and Gershwin, M.E. 2000. The pathogenesis of autoimmunity in New Zealand mice. *Semin. Arthritis Rheum.* **29**:385–399.
- Lacout, C., et al. 2003. A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. *Blood.* **102**:1282–1289.
- Setoguchi, R., Hori, S., Takahashi, T., and Sakaguchi, S. 2005. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. *J. Exp. Med.* **201**:723–735.
- Fisson, S., et al. 2003. Continuous activation of autoreactive CD4⁺ CD25⁺ regulatory T cells in the steady state. *J. Exp. Med.* **198**:737–746.
- Huehn, J., and Hamann, A. 2005. Homing to suppress: address codes for Treg migration. *Trends Immunol.* **26**:632–636.
- Lehmann, J., et al. 2002. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25⁺ as well as CD25⁻ regulatory T cells. *Proc. Natl. Acad. Sci. U. S. A.* **99**:13031–13036.
- Huehn, J., et al. 2004. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4⁺ regulatory T cells. *J. Exp.*



- Med.* **199**:303–313.
19. Siegmund, K., et al. 2005. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. *Blood*. **106**:3097–3104.
20. Suffia, I., Reckling, S.K., Salay, G., and Belkaid, Y. 2005. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. *J. Immunol.* **174**:5444–5455.
21. Fontenot, J.D., Rasmussen, J.P., Gavin, M.A., and Rudensky, A.Y. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat. Immunol.* **6**:1142–1151.
22. Salomon, B., et al. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. *Immunity*. **12**:431–440.
23. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. *Annu. Rev. Immunol.* **22**:531–562.
24. Snapper, S.B., et al. 2005. WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. *J. Leukoc. Biol.* **77**:993–998.
25. Westerberg, L., et al. 2005. Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. *Blood*. **105**:1144–1152.
26. Lim, H.W., Hillsamer, P., Banham, A.H., and Kim, C.H. 2005. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. *J. Immunol.* **175**:4180–4183.
27. Bystry, R.S., Aluvihare, V., Welch, K.A., Kallikourdis, M., and Betz, A.G. 2001. B cells and professional APCs recruit regulatory T cells via CCL4. *Nat. Immunol.* **2**:1126–1132.
28. Fields, M.L., et al. 2005. CD4+ CD25+ regulatory T cells inhibit the maturation but not the initiation of an autoantibody response. *J. Immunol.* **175**:4255–4264.
29. Wada, T., et al. 2001. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. *Proc. Natl. Acad. Sci. U. S. A.* **98**:8697–8702.
30. Ariga, T., et al. 2001. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. *J. Immunol.* **166**:5245–5249.
31. Wada, T., et al. 2004. Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. *Blood*. **104**:1270–1272.
32. Zhou, B., et al. 2005. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. *Nat. Immunol.* **6**:1047–1053.
33. Knibbs, R.N., et al. 1998. Alpha(1,3)-fucosyltransferase VII-dependent synthesis of P- and E-selectin ligands on cultured T lymphoblasts. *J. Immunol.* **161**:6305–6315.
34. Zhu, Q., et al. 1997. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. *Blood*. **90**:2680–2689.
35. Taneda, S., et al. 2001. Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. *Am. J. Pathol.* **159**:2355–2369.